The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pharmaceutical giant Pfizer (NYSE: PFE) and social media platform Snap (NYSE: SNAP) belong to this group: Both have ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Pfizer ($PFE) became a household name during the pandemic, and its stock rose along with its fame. However, three years later, the share price has ...

The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors.

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also ...

One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...